Bayer has previously invested about €1.3bn in more than 50 companies in the past seven years.
Leaps by Bayer, the corporate venturing unit of Germany-based drugs and crops company Bayer, has committed a further €1.3bn ($1.44bn) over the next three years to more than double the pace of spending to date.
The new investment plan was announced last month with a focus on cell and gene therapy (CGT) and precision health for consumers and innovations enable farmers to ensure food security and decarbonize agriculture.
Bayer has previously invested about €1.3bn in more than 50 companies in the…
